Optimal Duration of Oral Sildenafil for Perioperative Management of Severe Pulmonary Hypertension in Mitral Valve Replacement
DOI:
https://doi.org/10.53350/pjmhs02025195.3Keywords:
Rheumatic Heart Disease, Pulmonary Hypertension, Mitral Valve Surgery, Sildenafil, Perioperative Care.Abstract
Background: Rheumatic heart disease (RHD) involves the mitral valve in 50–60% of cases. Long-term mitral valve pathologies cause multiple sequelae in the form of atrial fibrillation, pulmonary hypertension, and heart failure. Sildenafil has been used as a therapy for the control of pulmonary hypertension, with emphasis on the perioperative period.
Aim: To investigate the influence of oral administration of sildenafil at different durations on intraoperative and postoperative pulmonary hypertension and to compare these effects with preoperative pulmonary pressures.
Methods: This comparative cross-sectional study was conducted at Department of Cardiac Surgery, King Edward Medical University/ Mayo Hospital Lahore between July 2024 and January 2025. Patients were divided into 2 groups. Patients enrolled in the short course of sildenafil were administered oral Sildenafil 50mg/5ml, 3 times a day for 2 days before surgery. And in the long course, the same regimen was given for 7 days.
Results: A Mann-Whitney U test showed that there was no significant difference in the preoperative mean pulmonary artery pressures between the groups receiving the short and long course of oral sildenafil (p-value 0.890). The reduction in mean pulmonary artery pressures from preoperative to postoperative was analyzed to be 16.46 ± 4.13 for the short course whereas it was 24.83 ± 5.04 for the long course and the difference between these two results was found to be statistically significant (p< 0.05, p< 0.001).
Conclusion: Sildenafil has been shown to be effective in the perioperative management of pulmonary hypertension in mitral valve surgery with longer duration of sildenafil administration leading to greater reduction in pressures.
References
Ray S. Changing epidemiology and natural history of valvular heart disease. Prendergast B, MacCarthy P, editors. Clin Med. 2010 Apr 1;10(2):168–71. DOI: 10.7861/clinmedicine.10-2-168
Gomes NFA, Silva VR, Levine RA, Esteves WAM, de Castro ML, Passos LSA, et al. Progression of Mitral Regurgitation in Rheumatic Valve Disease: Role of Left Atrial Remodeling. Front Cardiovasc Med. 2022 Mar 11;9:862382. DOI: 10.3389/fcvm.2022.862382
Mocumbi A, Humbert M, Saxena A, Jing ZC, Sliwa K, Thienemann F, et al. Pulmonary hypertension. Nat Rev Dis Primer. 2024 Jan 4;10(1):1–20. DOI: 10.1038/s41572-023-00486-7
Dass C, Kanmanthareddy A. Rheumatic Heart Disease. In: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Nov 6]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538286/
Maeder MT, Weber L, Buser M, Gerhard M, Haager PK, Maisano F, et al. Pulmonary Hypertension in Aortic and Mitral Valve Disease. Front Cardiovasc Med [Internet]. 2018 May 23 [cited 2025 May 22];5. Available from: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2018.00040/full
Hassoun PM. Pulmonary Arterial Hypertension. N Engl J Med. 2021 Dec 15;385(25):2361–76. DOI: 10.1056/NEJMra2000348
Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, et al. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension. Circulation. 2024 Jun 18;149(25):1949–59. DOI: 10.1161/CIRCULATIONAHA.123.068107
Villanueva DLE, Agustin RD, Llanes EJ. Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis. Cardiol Res. 2019 Nov 23;10(6):369. DOI: 10.14740/cr.v10i6.962
Ram E, Sternik L, Klempfner R, Eldar M, Goldenberg I, Peled Y, et al. Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery. J Cardiothorac Vasc Anesth. 2019 Jun 1;33(6):1648–56. DOI: 10.1053/j.jvca.2018.12.023
Gandhi H, Shah B, Patel R, Toshani R, Pujara J, Kothari J, et al. Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement. Indian J Pharmacol. 2014 Jun;46(3):281. DOI: 10.4103/0253-7613.132158
Mitra T, Das Baksi K, Mukherjee P. Effectiveness of sildenafil in pulmonary hypertension secondary to mitral valve disease [Internet]. [cited 2023 Apr 18]. Available from: https://www.amhsjournal.org/article.asp?issn=2321-4848; year=2020;volume=8;issue=2;spage=225;epage=229;aulast=Mitra
Tuder RM. Pulmonary Vascular Remodeling in Pulmonary Hypertension. Cell Tissue Res. 2017 Mar;367(3):643–9. DOI: 10.1007/s00441-016-2539-y
Bermejo J, Yotti R, García-Orta R, Sánchez-Fernández PL, Castaño M, Segovia-Cubero J, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018 Apr 14;39(15):1255–64. DOI: 10.1093/eurheartj/ehx700
Fikri YA, Mulia EP, Nugroho FW. Preoperative sildenafil in pediatric patients undergoing congenital heart surgeries: A systematic review and meta-analysis. In Seminars in Cardiothoracic and Vascular Anesthesia 2023 Dec (Vol. 27, No. 4, pp. 252-259). Sage CA: Los Angeles, CA: SAGE Publications.
Amin S, Menaissy Y, Abosenna WG. Early Outcome of the Effect of Phosphodiesterase-5 Inhibitor on Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery. International journal of health sciences.;5(S2):1479-90.
McGlothlin DP, Granton J, Klepetko W, Beghetti M, Rosenzweig EB, Corris PA, Horn E, Kanwar MK, McRae K, Roman A, Tedford R. ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. The Journal of Heart and Lung Transplantation. 2022 Sep 1;41(9):1135-94.
Patel B, D’Souza S, Sahni T, Yehya A. Pulmonary hypertension secondary to valvular heart disease: a state-of-the-art review. Heart Failure Reviews. 2024 Jan;29(1):277-86.
Omran AM, Fayed H. Should Near Systemic Pulmonary Hypertension be a Contraindication for Rheumatic Mitral Stenosis Valve surgery in Egyptian population?. Journal of Medicine in Scientific Research. 2023;6(1):1.
Muenster S, Zarragoikoetxea I, Moscatelli A, Balcells J, Gaudard P, Pouard P, Marczin N, Janssens SP. Inhaled NO at a crossroads in cardiac surgery: current need to improve mechanistic understanding, clinical trial design and scientific evidence. Frontiers in Cardiovascular Medicine. 2024 Apr 5;11:1374635.
Mohananey D, Martin AK, Mandawat H, Hauser JM, Ramakrishna H. Analysis of the 2022 European Society of Cardiology/European Respiratory Society Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Journal of Cardiothoracic and Vascular Anesthesia. 2024 Feb 1;38(2):534-41.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2025 SALIK AHMED CHEEMA, BENAZEER MIKRANI, ANEELA JUMADIN, MUHAMMAD MOHSIN MAHMOOD, MUHAMMAD YASIR, ATTAULLAH KHAN NIAZI
This work is licensed under a Creative Commons Attribution 4.0 International License.
